CINRYZE is plasma-derived C1-I NH approved for routine prevention (prophylaxis), short-term prevention or pre-procedure prevention, and acute attacks of HAE.
This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled study
The patent also covers the efficacy of the herbal composition in the management of metabolic syndrome disorders
LG Chem will receive totaling up to $95.5 million for the China rights
The current ruling will assure the safety of the use of Ranitidine for Indian patients
The Institute will focus on increasing preparedness and laboratory capabilities for identification of novel and unknown zoonotic agents
48-week data from MOMENTUM phase III clinical trial show momelotinib maintained total symptom response
GMP-compliant documentation of all manufacturing steps for cell and gene therapies
Antibody levels remained above baseline six months after completion of a three-dose (Month 0-2-6) or a two-dose (Month 0-6) vaccination schedule
Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival
Subscribe To Our Newsletter & Stay Updated
